421 related articles for article (PubMed ID: 26427914)
21. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
[TBL] [Abstract][Full Text] [Related]
22. Fucosyltransferase IV (FUT4) as an effective biomarker for the diagnosis of breast cancer.
Yan X; Lin Y; Liu S; Aziz F; Yan Q
Biomed Pharmacother; 2015 Mar; 70():299-304. PubMed ID: 25776515
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
[TBL] [Abstract][Full Text] [Related]
24. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
25. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
[TBL] [Abstract][Full Text] [Related]
26. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.
Misale S; Arena S; Lamba S; Siravegna G; Lallo A; Hobor S; Russo M; Buscarino M; Lazzari L; Sartore-Bianchi A; Bencardino K; Amatu A; Lauricella C; Valtorta E; Siena S; Di Nicolantonio F; Bardelli A
Sci Transl Med; 2014 Feb; 6(224):224ra26. PubMed ID: 24553387
[TBL] [Abstract][Full Text] [Related]
27. Targeted biotherapy in metastatic colorectal carcinoma: Current practice.
Cacheux W; Le Tourneau C; Baranger B; Mignot L; Mariani P
J Visc Surg; 2011 Feb; 148(1):12-8. PubMed ID: 21277276
[TBL] [Abstract][Full Text] [Related]
28. Biomarker-driven EGFR therapy improves outcomes in patients with metastatic colorectal cancer.
Hendifar A; Tan CR; Annamalai A; Tuli R
Expert Rev Anticancer Ther; 2014 Sep; 14(9):1051-61. PubMed ID: 24898788
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of fucosyltransferase IV promotes A431 cell proliferation through activating MAPK and PI3K/Akt signaling pathways.
Yang XS; Liu S; Liu YJ; Liu JW; Liu TJ; Wang XQ; Yan Q
J Cell Physiol; 2010 Nov; 225(2):612-9. PubMed ID: 20506505
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms and targeting of colorectal cancer.
Vanhoefer U
Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
[TBL] [Abstract][Full Text] [Related]
31. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenesis agents in colorectal cancer.
Hubbard J; Grothey A
Curr Opin Oncol; 2010 Jul; 22(4):374-80. PubMed ID: 20375894
[TBL] [Abstract][Full Text] [Related]
33. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
34. Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.
Ledys F; Derangère V; Réda M; Guion JF; Milliex R; Roux V; Limagne E; Arnould L; Bengrine L; Ghiringhelli F; Rébé C
Adv Ther; 2019 Jun; 36(6):1480-1484. PubMed ID: 30980281
[TBL] [Abstract][Full Text] [Related]
35. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Meyerhardt JA; Heseltine D; Ogino S; Clark JW; Enzinger PC; Ryan DP; Earle CC; Zhu AX; Fuchs CS
Clin Colorectal Cancer; 2006 May; 6(1):59-65. PubMed ID: 16796793
[TBL] [Abstract][Full Text] [Related]
37. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
[TBL] [Abstract][Full Text] [Related]
38. Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies.
Patel GS; Ullah S; Beeke C; Hakendorf P; Padbury R; Price TJ; Karapetis CS
Cancer Med; 2015 Oct; 4(10):1461-71. PubMed ID: 26211512
[TBL] [Abstract][Full Text] [Related]
39. Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer.
Koustas E; Karamouzis MV; Mihailidou C; Schizas D; Papavassiliou AG
Cancer Lett; 2017 Jun; 396():94-102. PubMed ID: 28323034
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer.
Hong CS; Sun EG; Choi JN; Kim DH; Kim JH; Ryu KH; Shim HJ; Hwang JE; Bae WK; Kim HR; Kim KK; Jung C; Chung IJ; Cho SH
Cancer Sci; 2020 Sep; 111(9):3268-3278. PubMed ID: 32533590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
